Related Experiment Video
Updated: Jun 21, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Inhibiting the inhibitors: retro-inverso Smac peptides
Julia Hossbach1, Elke Michalsky, Peter Henklein
1Charité - Universitätsmedizin Berlin, Institute of Physiology, Structural Bioinformatics Group, Arnimallee 22, 14195 Berlin, Germany. Julia.Hossbach@charite.de
Abstract:
Resistance against apoptosis-inducing anti-cancer drugs remains a severe problem in therapy. One reason is the overexpression of inhibitors of apoptosis proteins (IAPs), a group of proteins responsible for the prevention of apoptosis induction by inactivation of initiator caspases. The natural inhibitor of the IAPs is the protein Smac, which impedes the binding to the caspases. Although Smac is a potent inhibitor, Smac peptides are not very stable in vivo and thus not applicable in therapy. Bioinformatical methods were applied to design Smac-derived peptides to break the therapy resistance in IAP high-expressing tumor cells. The exchange of amino acids in the Smac peptides AVPI and AVPF against unnatural amino acids leads to an improvement of the apoptosis sensitivity. The variety of Smac peptides was filtered by computational docking. Moreover, Smac-derived peptides with sufficient binding to the IAPs were tested in IAP-expressing Hodgkin Lymphoma cell lines.
Insights
Scientists designed Smac-derived peptides using bioinformatics to overcome resistance to apoptosis-inducing anti-cancer drugs. These modified peptides improve cancer cell sensitivity to apoptosis, offering a potential new therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Resistance to apoptosis-inducing anti-cancer drugs is a major therapeutic challenge.
- Overexpression of Inhibitors of Apoptosis Proteins (IAPs) prevents cancer cell death.
- Natural Smac peptides are unstable in vivo, limiting their therapeutic use.
Purpose of the Study:
- To design novel Smac-derived peptides to overcome IAP-mediated therapy resistance.
- To enhance the stability and efficacy of Smac peptides for cancer treatment.
- To identify Smac peptides that can re-sensitize IAP-high expressing tumor cells to apoptosis.
Main Methods:
- Bioinformatic approaches were used to design Smac-derived peptides.
- Amino acid substitutions with unnatural amino acids were employed to improve peptide stability and function.
- Computational docking was utilized to filter and select promising peptide candidates.
- In vitro testing of Smac-derived peptides in Hodgkin Lymphoma cell lines.
Main Results:
- Smac-derived peptides incorporating unnatural amino acids demonstrated improved apoptosis sensitivity in tumor cells.
- Computational docking successfully identified Smac peptides with significant binding affinity to IAPs.
- Tested peptides showed potential in re-sensitizing IAP-expressing Hodgkin Lymphoma cells.
Conclusions:
- Bioinformatically designed Smac-derived peptides offer a promising strategy to combat anti-cancer drug resistance.
- Unnatural amino acid incorporation enhances the therapeutic potential of Smac peptides.
- These novel peptides warrant further investigation for cancer therapy, particularly in IAP-overexpressing tumors.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Feedback Inhibition
Enzyme Inhibition
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
